文献速递乳腺癌

APHINITY二次分析:手动、数字与AI评估肿瘤浸润淋巴细胞

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

该研究基于APHINITY三期试验的4262例HER2阳性早期乳腺癌样本,比较手动、数字和AI方法量化间质肿瘤浸润淋巴细胞(sTIL)及AI空间特征的预后与治疗获益分层价值。AI免疫热点评分提供独立补充信息。

核心结论

  • 标准化手动sTIL评分可重现,数字和AI方法显示一致的预后分层及治疗获益分层潜力。
  • AI空间指标提供超越sTIL密度的补充信息,可能支持更可扩展的免疫评估。

研究设计与样本

  • APHINITY三期随机试验的二次分析,纳入4262例H&E染色图像。
  • 采用手动评估、自动数字方法、AI淋巴细胞百分比及两种AI空间特征(AI-TIL和免疫热点)进行分析。
  • 在262例随机选择的肿瘤样本中由5位病理学家独立评分评估观察者间重现性。

主要发现

  • 手动与自动方法一致性中等。

临床怎么用

  • 标准化手动sTIL评分可用于HER2阳性早期乳腺癌的预后评估。
  • AI评分和空间指标可能辅助识别从双HER2阻断中获益更多的患者。
  • AI空间指标可补充sTIL密度信息,支持更可扩展的免疫评估。

局限性

  • 需要在独立队列中验证这些方法。
  • 其在当代HER2靶向治疗分层中的临床效用尚需明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stromal tumour-infiltrating lymphocytes (sTILs) are prognostic in early-stage HER2-positive breast cancer, but their role in the context of dual HER2 blockade remains undefined. We evaluated manual, digital, and artificial intelligence (AI)-based sTIL quantification, together with AI-derived spatial metrics, for prognostic and treatment-benefit stratification using tumour samples from the phase 3 APHINITY trial. METHODS: In the APHINITY trial, 4805 patients were randomly assigned to receive chemotherapy plus trastuzumab with pertuzumab or chemotherapy plus trastuzumab with placebo. Median follow-up was 74·1 months (IQR 68·3-75·4). We analysed 4262 haematoxylin and eosin-stained images using manual assessment, an automated digital approach, AI-based lymphocyte quantification (AI percentage lymphocytes), and two AI-derived spatial features (AI-TIL and immune hotspot). Interobserver reproducibility was assessed in 262 randomly chosen tumour samples scored independently by five pathologists. Multivariable Cox models were used to assess associations between TIL levels and invasive disease-free survival (primary outcome in APHINITY), distant recurrence-free interval, and overall survival. The heterogeneity of pertuzumab benefit was evaluated using subgroup analyses, subpopulation treatment effect pattern plot analyses, and nested Cox models with treatment-by-biomarker interaction terms. FINDINGS: Manual scoring showed high interobserver reproducibility (intraclass correlation coefficient 0·84 [95% CI 0·79-0·88]). Concordance between manual and automated methods was modest. AI-based scoring (AI percentage lymphocytes) reclassified 120 (11·6%) of 1035 node-positive tumours from immune-low (by manual scoring) to immune-high; this subgroup of patients showed greater separation of 5-year invasive disease-free survival curves between pertuzumab and placebo groups compared with patients whose tumours were concordantly classified as immune-low by both manual and AI-based approaches. Higher levels of TILs were associated with improved invasive disease-free survival for all sTIL measurement approaches and spatial measurements (hazard ratios [HRs] 0·41-0·93). Pertuzumab was associated with improved invasive disease-free survival at higher sTIL levels across all measurement approaches (HRs 0·36-0·48), but was not associated with higher values of spatial measures. The largest 6-year absolute improvements with pertuzumab were observed in patients with node-positive disease whose tumours scored in the highest level of immune infiltration of manual sTIL scoring (≥70·0%; mean absolute improvement 12·1 percentage points [SD 2·8]). In nested prognostic and predictive models, AI-based immune hotspot scores provided the most consistent additional information when combined with any sTIL measurement (all p<0·010). INTERPRETATION: Standardised manual sTIL scoring was reproducible, and digital and AI-based methods showed consistent prognostic stratification and potential for treatment-benefit stratification despite only modest correlation between platforms. AI spatial metrics provided complementary information beyond sTIL density and could support more scalable immune assessment. Future studies are needed to validate these approaches in independent cohorts and to clarify their clinical utility for stratifying contemporary HER2-directed therapies. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lara González LE, Giudici F, Salgado R, et al. Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial. Lancet Oncol. 2026. PMID: 42636838. doi:10.1016/S1470-2045(26)00247-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。